Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) announced that Chief Executive Officer Robb Knie is scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference (NobleCon) in Boca Raton, FL.
The conference runs December 2–3, 2025; the company provided registration and one-on-one meeting details via the NobleCon website for investors and attendees.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, HOTH declined 5.79%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Two biotech peers in the momentum scanner (PASG, XCUR) showed down moves (median about -8.6%), while HOTH’s pre-news move was +1.68%, pointing to stock-specific behavior rather than a synchronized sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Pipeline update | Positive | +5.3% | Comprehensive update on four clinical and preclinical programs with near-term milestones. |
| Dec 01 | Conference appearance | Neutral | -5.8% | CEO presentation at NobleCon investor conference and meeting opportunities. |
| Nov 20 | AI collaboration | Positive | -10.4% | Acceptance into NVIDIA Connect Program to support AI-accelerated R&D workflows. |
| Oct 27 | New study launch | Positive | +1.1% | VA-backed preclinical GDNF program targeting obesity and fatty liver disease. |
| Oct 21 | Orphan designation | Positive | +3.6% | FDA Orphan Drug Designation and strong preclinical data for HT-KIT in rare cancers. |
Recent news has produced mixed price reactions, with several positive clinical and strategic updates seeing both aligned gains and divergences where shares fell despite favorable developments.
This announcement highlights Hoth’s participation in an investor conference, consistent with its pattern of active outreach via presentations and 8-K investor decks. Over the last few months, Hoth reported FDA Orphan Drug Designation for HT-KIT, launched a VA-backed GDNF obesity program, and issued a broad pipeline update on Dec 03, 2025. It also joined the NVIDIA Connect Program to bolster AI-driven R&D. Past “news” items, including conference-related updates, have sometimes led to negative price reactions despite largely neutral content.
Regulatory & Risk Context
An effective Form S-3 mixed shelf filed on Nov 14, 2025 allows Hoth to offer up to $50 million in various securities plus resale of 1,279,587 shares over time, giving flexibility to raise capital via prospectus supplements. This capacity, alongside an active ATM program disclosed in recent filings, is a key factor when assessing potential future equity issuance.
Market Pulse Summary
The stock moved -5.8% in the session following this news. A negative reaction despite neutral conference news fits the pattern seen when prior outreach or AI-partnership announcements led to declines despite constructive content. Investors have weighed funding needs and a $50 million mixed shelf alongside operating losses, which can pressure sentiment. Any sharp move could also be influenced by thin liquidity, as recent trading volume of 87,143 shares sat well below the 20-day average.
AI-generated analysis. Not financial advice.
NobleCon is the preeminent showcase of small and microcap companies
To learn more about NobleCon and registration to attend or scheduling a one-on-one meeting with management please visit https://nobleconference.com/
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference-december-2-3-2025-302627030.html
SOURCE Hoth Therapeutics, Inc.
FAQ
When will Hoth Therapeutics (HOTH) present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference?
Who will represent Hoth Therapeutics (HOTH) at the December 2025 NobleCon presentation?
How can investors register or request a one-on-one meeting with Hoth Therapeutics (HOTH) at NobleCon?
Where is the Noble Capital Markets Emerging Growth Equity Conference taking place for Hoth Therapeutics' presentation?
Does Hoth Therapeutics (HOTH) provide investor materials or webcast details for the NobleCon presentation?
